CN102170903B - 用于刺激免疫反应的产品和方法 - Google Patents

用于刺激免疫反应的产品和方法 Download PDF

Info

Publication number
CN102170903B
CN102170903B CN200980125581.9A CN200980125581A CN102170903B CN 102170903 B CN102170903 B CN 102170903B CN 200980125581 A CN200980125581 A CN 200980125581A CN 102170903 B CN102170903 B CN 102170903B
Authority
CN
China
Prior art keywords
cells
antigen
specific
bcr
hel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980125581.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102170903A (zh
Inventor
法存多·巴蒂斯塔
尤利娅·埃克尔-多尔纳
帕特里西亚·巴拉尔
温琴佐·塞伦多罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Blink Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Blink Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Publication of CN102170903A publication Critical patent/CN102170903A/zh
Application granted granted Critical
Publication of CN102170903B publication Critical patent/CN102170903B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200980125581.9A 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法 Expired - Fee Related CN102170903B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02
US61/049,814 2008-05-02
PCT/GB2009/001111 WO2009133378A2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Publications (2)

Publication Number Publication Date
CN102170903A CN102170903A (zh) 2011-08-31
CN102170903B true CN102170903B (zh) 2016-04-06

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980125581.9A Expired - Fee Related CN102170903B (zh) 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法

Country Status (8)

Country Link
US (1) US20110280930A1 (enExample)
EP (3) EP2288381A2 (enExample)
JP (3) JP5721620B2 (enExample)
CN (1) CN102170903B (enExample)
AU (1) AU2009241645B2 (enExample)
CA (1) CA2723226A1 (enExample)
ES (1) ES2570973T3 (enExample)
WO (1) WO2009133378A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288381A2 (en) * 2008-05-02 2011-03-02 Cancer Research Technology Limited Products and methods for stimulating an immune response
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN107115314B (zh) 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
WO2014133106A1 (ja) * 2013-02-27 2014-09-04 独立行政法人理化学研究所 アレルギー疾患治療薬
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
AU2015269412B2 (en) * 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11150242B2 (en) * 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
AU2016277471A1 (en) * 2015-06-10 2018-01-04 Astrid TSCHIERSCH-PFREUNDSCHUH Means and methods for treatment of B-cell malignancies
WO2017136837A1 (en) 2016-02-06 2017-08-10 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
NL2017204B1 (en) * 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
WO2017211314A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
CN110114468A (zh) * 2016-08-17 2019-08-09 奥比思健康解决方案有限责任公司 靶向肿瘤的珠载体及其使用方法
AU2018316253A1 (en) * 2017-08-10 2020-01-16 Dana-Farber Cancer Institute, Inc. LMP1-expressing cells and methods of use thereof
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
JP2022514568A (ja) 2018-12-17 2022-02-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用
CN116286631A (zh) * 2023-02-15 2023-06-23 上海长征医院 一种利用CD79b单克隆抗体诱导构建B细胞免疫无能模型及其构建方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
ES2092560T5 (es) 1989-12-22 2004-09-16 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FI933580L (fi) 1991-02-15 1993-10-13 Uab Research Foundation Strukturgen av pneumokockprotein
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CA2196311A1 (en) 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
WO2004016283A2 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
AU2005259685B2 (en) 2004-07-07 2010-04-08 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
ES2625905T3 (es) * 2004-10-01 2017-07-20 Midatech Ltd. Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores
DE602006008278D1 (de) * 2005-03-02 2009-09-17 Pharmazeutische zusammensetzung
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
EP2288381A2 (en) * 2008-05-02 2011-03-02 Cancer Research Technology Limited Products and methods for stimulating an immune response
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B CELLS EXTRACT AND PRESENT IMMOBILIZATION ANTIGEN: IMPLICATIONS FOR AFFINITY DISCRIMINATION;BATISTA F D ET AL;《EMBO JOURNAL》;20000130;第19卷(第4期);第513-520页 *
Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen;PEDERSEN M K ET AL;《JOURNAL OF IMMUNOLOGICAL METHODS》;20060420;第311卷(第1-2期);第198-206页 *
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma;PAUL NEESON ET AL;《CANCER IMMUNOLOGY, IMMUNOTHERAPY》;20070918;第57卷(第4期);第493-505页 *
Multivalent compounds for antigen-specific B cell tolerance and treatment of autoimmune diseases.;JONES DAVID S;《CURRENT MEDICINAL CHEMISTRY 2005》;20051231;第12卷(第16期);第1887-1904页 *

Also Published As

Publication number Publication date
EP2711020A1 (en) 2014-03-26
EP2711021B1 (en) 2016-03-09
CA2723226A1 (en) 2009-05-11
JP5721620B2 (ja) 2015-05-20
HK1190942A1 (en) 2014-07-18
WO2009133378A3 (en) 2009-12-23
JP2011519847A (ja) 2011-07-14
HK1191548A1 (en) 2014-08-01
EP2288381A2 (en) 2011-03-02
JP2015028023A (ja) 2015-02-12
EP2711021A1 (en) 2014-03-26
US20110280930A1 (en) 2011-11-17
JP2015038066A (ja) 2015-02-26
HK1161542A1 (zh) 2012-07-27
EP2711020B1 (en) 2016-08-10
ES2570973T3 (es) 2016-05-23
AU2009241645B2 (en) 2014-07-17
AU2009241645A1 (en) 2009-11-05
WO2009133378A2 (en) 2009-11-05
CN102170903A (zh) 2011-08-31
JP5853068B2 (ja) 2016-02-09

Similar Documents

Publication Publication Date Title
JP5853068B2 (ja) 免疫応答を刺激するための作製物および方法
Pedersen et al. Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses
US9950025B2 (en) Compositions and methods for treatment of neoplastic disease
BRPI0616770A2 (pt) modulação de respostas imunes mediadas por tlr empregando oligonucleotìdeos adaptadores
JP2014058525A (ja) カチオン脂質による免疫応答の刺激
EP4313160A1 (en) Targeting multiple t cell types using spherical nucleic acid vaccine architecture
WO2001094949A2 (en) Soluble cd1 compositions and uses thereof
AU2016240410B2 (en) Pain treatment
WO2024086799A2 (en) Lipid nanoparticles and methods of using the same for treating cell proliferative diseases and disorders
AU2014250631B2 (en) Products and methods for stimulating an immune response
HK1161542B (en) Products and methods for stimulating an immune response
US20210015914A1 (en) Methods and compositions related to accelerated humoral affinity
HK1190942B (en) Products and methods for stimulating an immune response
HK1191548B (en) Products and methods for stimulating an immune response
HK1191562A (en) Method for suppressing an immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161542

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151016

Address after: English Marlowe

Applicant after: Cancer Rec Tech Ltd.

Address before: London, England

Applicant before: Cancer Rec Tech Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160406

Termination date: 20170505

CF01 Termination of patent right due to non-payment of annual fee